In addition to their efficacy in reducing intravascular hemolysis, C5 inhibitors have been associated with a reduction in thrombotic events, a major cause of morbidity and mortality in PNH patients [6]. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.